EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 February 2015
EMA/CVMP/36684/2015
Committee for Medicinal Products for Veterinary Use

# Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits

## Procedure no: EMEA/V/MRL/003307/EXTN/0003

## Name of the substance: Diethylene glycol monoethyl ether (INN)

### Basis for the opinion

Pursuant to Article 3 of Regulation (EC) No 470/2009 of 6 May 2009, Intervet International B.V. submitted to the European Medicines Agency on 22 August 2014 an application for the extension of maximum residue limits for diethylene glycol monoethyl ether to poultry.

### Recommendation

The Committee, having considered the application, recommends by consensus the extension of maximum residue limits for diethylene glycol monoethyl ether to poultry. Furthermore, and with reference to Article 5 of Regulation (EC) No 470/2009, the Committee agreed to extrapolate the conclusions to all food producing species, and therefore recommends by consensus the amendment of the entry for diethylene glycol monoethyl ether in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

| Pharmaco-logically active substance | Marker residue | Animal species | MRLs | Target tissues | Other provisions | Therapeutic classification |
|---|---|---|---|---|---|---|
| Diethylene glycol monoethyl ether | NOT APPLICABLE | All food producing species | No MRL required | NOT APPLICABLE | NO ENTRY | NO ENTRY |

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5545
**Send a question via our website** www.ema.europa.eu/contact

The Icelandic CVMP member agrees with the above-mentioned recommendation of the Committee.

The scientific conclusions of the Committee are presented in the European public MRL assessment report (EPMAR), provided in Annex I of this opinion.

The present opinion is forwarded to the European Commission and to the applicant together with its appendices.

London, 12 February 2015

*Signature on file*

Dr. A. Holm
Chair, on behalf of the CVMP

# Annex I

## European public MRL assessment report (EPMAR)